Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.
The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC), una società biotecnologica in fase clinica specializzata in terapie cellulari per malattie autoimmuni, ha assegnato premi di incentivazione all'assunzione a due nuovi dipendenti. La società ha emesso opzioni su azioni per l'acquisto di 5.750 azioni a un prezzo di esercizio di 12,48 $ per azione il 4 agosto 2025.
Le opzioni sono state concesse nell'ambito del Piano di Incentivazione all'Assunzione Emendato e Riformulato 2018 della Società, con un piano di maturazione quadriennale. Il 25% iniziale matura il 4 agosto 2026, seguito da tre rate annuali uguali, con piena maturazione entro il 4 agosto 2029. Le opzioni hanno una durata di dieci anni e sono state concesse secondo la Regola Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica centrada en terapias celulares para enfermedades autoinmunes, ha otorgado premios de incentivo por contratación a dos nuevos empleados. La compañía emitió opciones sobre acciones para comprar 5,750 acciones a un precio de ejercicio de $12.48 por acción el 4 de agosto de 2025.
Las opciones se otorgaron bajo el Plan de Premios de Incentivo por Contratación Enmendado y Reformulado 2018 de la Compañía, con un programa de adquisición de derechos de cuatro años. El 25% inicial se adquiere el 4 de agosto de 2026, seguido por tres pagos anuales iguales, completándose la adquisición total para el 4 de agosto de 2029. Las opciones tienen un plazo de diez años y se otorgaron bajo la Regla Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC)는 자가면역 질환을 위한 세포 치료에 집중하는 임상 단계의 바이오테크 회사로, 두 명의 신입 직원에게 고용 유인 보상을 부여했습니다. 회사는 2025년 8월 4일에 주당 $12.48의 행사 가격으로 5,750주의 주식 매수 옵션을 발행했습니다.
이 옵션은 회사의 2018년 개정 및 재작성된 고용 유인 인센티브 보상 계획에 따라 부여되었으며, 4년 간의 베스팅 일정이 적용됩니다. 초기 25%는 2026년 8월 4일에 베스팅되며, 이후 3년간 매년 동일한 비율로 베스팅되어 2029년 8월 4일까지 완전히 베스팅됩니다. 옵션의 유효 기간은 10년이며, Nasdaq 규칙 5635(c)(4)에 따라 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une société biotechnologique en phase clinique spécialisée dans la thérapie cellulaire pour les maladies auto-immunes, a accordé des primes d'incitation à l'embauche à deux nouveaux employés. La société a émis des options d'achat d'actions pour 5 750 actions à un prix d'exercice de 12,48 $ par action le 4 août 2025.
Les options ont été accordées dans le cadre du Plan d'Incitation à l'Embauche modifié et révisé de 2018 de la société, avec un calendrier d'acquisition des droits sur quatre ans. Les 25 % initiaux seront acquis le 4 août 2026, suivis de trois versements annuels égaux, l'acquisition complète étant atteinte au 4 août 2029. Les options ont une durée de dix ans et ont été accordées conformément à la règle Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC), ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Zelltherapien für Autoimmunerkrankungen, hat zwei neuen Mitarbeitern Anreizprämien gewährt. Das Unternehmen hat am 4. August 2025 Aktienoptionen zum Kauf von 5.750 Aktien zu einem Ausübungspreis von 12,48 $ pro Aktie ausgegeben.
Die Optionen wurden im Rahmen des geänderten und neu gefassten Anreizprämienplans für Neueinstellungen von 2018 des Unternehmens gewährt und unterliegen einem Vierjahres-Vesting-Zeitplan. Die anfänglichen 25 % vesten am 4. August 2026, gefolgt von drei gleichen jährlichen Raten, sodass die Optionen bis zum 4. August 2029 vollständig vesten. Die Optionen haben eine Laufzeit von zehn Jahren und wurden gemäß Nasdaq-Regel 5635(c)(4) gewährt.
- None.
- None.
FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On August 4, 2025, the Company issued to these employees options to purchase an aggregate of 5,750 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What stock options did Cartesian Therapeutics (RNAC) grant to new employees in August 2025?
What is the vesting schedule for RNAC's August 2025 employee stock options?
Under what plan were Cartesian Therapeutics' employee stock options granted?
When do the RNAC employee stock options expire?
